Associated Papers
Identification and analysis of oncogenic non-synonymous single nucleotide polymorphisms in the human NRAS gene: An exclusive in silico study.
Mozibullah M et al.
Journal, Genetic Engineering & Biotechnology, 2024
38797553 (PubMed )
Supplement: mmc1.xlsx › Table_1
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M et al.
Nature, 2024
38589574 (PubMed )
Supplement: 41586_2024_7205_MOESM5_ESM.xlsx › ED_Fig_10
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H et al.
Cancer Communications (london, England), 2023
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A et al.
Cancer Discovery, 2022
35404998 (PubMed )
Supplement: cd-22-0158_supplementary_tables_suppst1-st7.docx
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D et al.
Molecular Cancer, 2021
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacological Research, 2021
Select a paper to view details